Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.

JAMA cardiology

AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM.
PMID: 34431962
JAMA Cardiol. 2021 Nov 01;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070.

IMPORTANCE: Heart failure (HF) with preserved ejection fraction (HFpEF) is common, is frequently associated with ventricular wall thickening, and has no effective therapy. Transthyretin amyloid cardiomyopathy (ATTR-CM) can cause the HFpEF clinical phenotype, has highly effective therapy, and is...

Cite
AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-1274doi: 10.1001/jamacardio.2021.3070.
AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., Noseworthy, P. A., Johnson, G. B., Dunlay, S. M., Borlaug, B. A., Chareonthaitawee, P., Roger, V. L., Dispenzieri, A., Grogan, M., & Redfield, M. M. (2021). Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA cardiology, 6(11), 1267-1274. https://doi.org/10.1001/jamacardio.2021.3070
AbouEzzeddine, Omar F, et al. "Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction." JAMA cardiology vol. 6,11 (2021): 1267-1274. doi: https://doi.org/10.1001/jamacardio.2021.3070
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 01;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070. PMID: 34431962; PMCID: PMC8387947.
Copy Download .nbib Format: NLM
A case of intraorbital hemangioma diagnosed with tc 99m labeled erythrocyte scintigraphy and magnetic resonance imaging.

Molecular imaging and radionuclide therapy

Balcı TA, Koc ZP, Turgut B, Aydın AM, Busra Demirel B.
PMID: 23486921
Mol Imaging Radionucl Ther. 2011 Apr;20(1):26-8. doi: 10.4274/MIRT.20.05. Epub 2011 Apr 01.

UNLABELLED: We present a 20 year-old male patient who had prominent positional proptosis of the right eye and admitted to the hospital for tonsillectomy operation. After conventional ophthalmological examination, magnetic resonance imaging (MRI) and Tc 99m labeled erythrocyte scintigraphy...

Cite
Balcı TA, Koc ZP, Turgut B, et al. A case of intraorbital hemangioma diagnosed with tc 99m labeled erythrocyte scintigraphy and magnetic resonance imaging. Mol Imaging Radionucl Ther. 2011;20(1):26-8doi: 10.4274/MIRT.20.05.
Balcı, T. A., Koc, Z. P., Turgut, B., Aydın, A. M., & Busra Demirel, B. (2011). A case of intraorbital hemangioma diagnosed with tc 99m labeled erythrocyte scintigraphy and magnetic resonance imaging. Molecular imaging and radionuclide therapy, 20(1), 26-8. https://doi.org/10.4274/MIRT.20.05
Balcı, Tansel Ansal, et al. "A case of intraorbital hemangioma diagnosed with tc 99m labeled erythrocyte scintigraphy and magnetic resonance imaging." Molecular imaging and radionuclide therapy vol. 20,1 (2011): 26-8. doi: https://doi.org/10.4274/MIRT.20.05
Balcı TA, Koc ZP, Turgut B, Aydın AM, Busra Demirel B. A case of intraorbital hemangioma diagnosed with tc 99m labeled erythrocyte scintigraphy and magnetic resonance imaging. Mol Imaging Radionucl Ther. 2011 Apr;20(1):26-8. doi: 10.4274/MIRT.20.05. Epub 2011 Apr 01. PMID: 23486921; PMCID: PMC3590937.
Copy Download .nbib Format: NLM
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.

JAMA cardiology

AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM.
PMID: 34431962
JAMA Cardiol. 2021 Nov 01;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070.

IMPORTANCE: Heart failure (HF) with preserved ejection fraction (HFpEF) is common, is frequently associated with ventricular wall thickening, and has no effective therapy. Transthyretin amyloid cardiomyopathy (ATTR-CM) can cause the HFpEF clinical phenotype, has highly effective therapy, and is...

Cite
AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-1274doi: 10.1001/jamacardio.2021.3070.
AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., Noseworthy, P. A., Johnson, G. B., Dunlay, S. M., Borlaug, B. A., Chareonthaitawee, P., Roger, V. L., Dispenzieri, A., Grogan, M., & Redfield, M. M. (2021). Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA cardiology, 6(11), 1267-1274. https://doi.org/10.1001/jamacardio.2021.3070
AbouEzzeddine, Omar F, et al. "Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction." JAMA cardiology vol. 6,11 (2021): 1267-1274. doi: https://doi.org/10.1001/jamacardio.2021.3070
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 01;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070. PMID: 34431962; PMCID: PMC8387947.
Copy Download .nbib Format: NLM
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.

JAMA cardiology

AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM.
PMID: 34431962
JAMA Cardiol. 2021 Nov 01;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070.

IMPORTANCE: Heart failure (HF) with preserved ejection fraction (HFpEF) is common, is frequently associated with ventricular wall thickening, and has no effective therapy. Transthyretin amyloid cardiomyopathy (ATTR-CM) can cause the HFpEF clinical phenotype, has highly effective therapy, and is...

Cite
AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-1274doi: 10.1001/jamacardio.2021.3070.
AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., Noseworthy, P. A., Johnson, G. B., Dunlay, S. M., Borlaug, B. A., Chareonthaitawee, P., Roger, V. L., Dispenzieri, A., Grogan, M., & Redfield, M. M. (2021). Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA cardiology, 6(11), 1267-1274. https://doi.org/10.1001/jamacardio.2021.3070
AbouEzzeddine, Omar F, et al. "Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction." JAMA cardiology vol. 6,11 (2021): 1267-1274. doi: https://doi.org/10.1001/jamacardio.2021.3070
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 01;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070. PMID: 34431962; PMCID: PMC8387947.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries